Injectable Anti-Snake Venom: Indications and Administration
Antivenom is the definitive treatment for venomous snakebite and should be administered in a hospital setting for any patient with progressive venom injury, defined as worsening local swelling/ecchymosis, clinically important coagulation abnormalities, or systemic effects like hypotension or altered mental status 1, 2.
Indications for Antivenom Administration
Antivenom is NOT available in the first aid setting and should only be given after hospital arrival 1. The key indication is progressive envenomation, which includes:
- Local injury progression: Advancing swelling, ecchymosis, or tissue damage beyond the bite site
- Coagulation dysfunction: Prolonged clotting time, bleeding diathesis, or incoagulable blood
- Systemic manifestations: Hypotension, altered mental status, muscle fasciculations, paralysis, or respiratory compromise
- Neurotoxic signs: Particularly with coral snake (Elapidae) bites causing paralysis 1
Critical timing consideration: Early antivenom administration is essential, as some venom effects (pre-synaptic neurotoxicity, myotoxicity) are irreversible once established 3. Systemic symptoms like nausea, vomiting, headache, and abdominal pain should trigger immediate consideration for antivenom 3.
Administration Protocol
Dosing by Severity
The 2024 AHA/Red Cross guidelines emphasize that antivenom dosing depends on envenomation severity 1:
- Mild envenomation: Up to 5 vials initially
- Moderate envenomation: 10-15 vials
- Severe envenomation: 15-20 vials or more 4
For pit viper bites in North America: The current FDA-approved antivenoms are FabAV (CroFab) and F(ab')₂ formulations 5, 2, 6. The expert consensus recommends stocking 12 vials for 8-hour treatment and 18 vials for 24-hour treatment 5.
Route and Preparation
- Intravenous administration ONLY - antivenom is only effective when given IV 2, 4
- Mandatory skin testing before administration to predict anaphylactic reactions 4
- Have diphenhydramine and epinephrine immediately available at bedside for potential anaphylaxis 4
- Fab fragments enter solution quickly, shortening time to administration 2
Monitoring and Repeat Dosing
Critical pitfall: Initial dosing may be insufficient, particularly with severe coagulopathy 7:
- Monitor clotting time every 6 hours after initial dose
- Patients with incoagulable blood at presentation often require 150-200 mL total (higher initial doses recommended) 7
- Recurrence of coagulopathy occurs in ~35% of patients even after correction, requiring continued monitoring 7
- Subsequent doses: 50-100 mL depending on degree of ongoing dysfunction 7
Important consideration with Fab antivenoms: Fab molecules have shorter half-lives than IgG, potentially allowing recurrence of venom effects if additional doses are not given 2. This requires vigilant monitoring for 24+ hours.
Special Populations
Centruroides (scorpion) envenomation: Stock 3 vials of F(ab')₂ antivenom 5. Administer for severe systemic symptoms including respiratory compromise in children 1.
What NOT to Do
The 2024 guidelines explicitly state these interventions are potentially harmful 1:
- No tourniquets - worsen local tissue injury
- No pressure immobilization bandaging - potentially harmful for cytotoxic venom (>95% of North American bites)
- No suction/incision - ineffective for venom removal, causes tissue injury
- No ice application - unproven benefit, may cause tissue injury
- No electric shock - ineffective and potentially harmful
Pre-Hospital Management
While awaiting transport for antivenom administration 1:
- Activate emergency services immediately for any venomous or possibly venomous bite
- Rest and immobilize the bitten extremity - minimize exertion to reduce systemic venom absorption
- Remove rings and constricting objects from affected limb before swelling progresses
- Transport by EMS for supportive care en route
The evidence strongly supports that definitive antivenom treatment cannot occur in first aid settings and requires hospital-based administration with appropriate monitoring and resuscitation capabilities 1.